BUY State Bank of India

One-off retirement provisions hurt profitability

BFSI - Banks > Result Update > February 4, 2024

SBI reported near in-line PPoP, but higher staff cost, including one-off retirement provision (Rs71bn) due to adverse court judgement in 2022 case, led to 37% PAT miss at Rs91.6bn/1% RoA. Credit growth improved 15% YoY/5% QoQ, leading to higher LDR at 75%, but higher funding cost led to a 7bps QoQ decline in NIM to 3.2%. Despite higher slippages QoQ because of recognition of BGR Energy, headline NPAs continued to trend down to 2.4%. Going forward, the bank expects growth to remain range-bound, while margin should stabilize, aided by better LDR and recent rate hike. Staff cost could remain elevated in Q4 due to pending wage revision/retirement provision of Rs54bn. SBI's CET-1 stands low at 10.4% (incl. 9M profits) and, thus, it has now indicated to raise capital soon. We trim our FY24 estimates by 6%, factoring in higher staff cost, but we have revised upward FY25/26 estimates by 3%/9% due to better margins, treasury performance, and sustained lower LLP. We retain BUY with a revised TP of Rs750, rolling forward on Dec-25E standalone Bank ABV, and have revised subsidiaries/investments value at Rs210/share (vs. Rs185).

State Bank of India:	Financial S	napshot (S	tandalone)		
Y/E March (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Net profit	390,943	502,325	585,792	685,955	771,498
Loan growth (%)	11.6	17.0	14.5	13.2	15.0
NII growth (%)	9.0	20.0	9.5	9.8	10.8
NIM (%)	2.8	3.0	3.0	2.9	2.9
PPOP growth (%)	5.2	11.2	(0.5)	32.6	15.4
Adj. EPS (Rs)	43.8	56.3	65.6	76.9	86.4
Adj. EPS growth (%)	91.5	28.5	16.6	17.1	12.5
Adj. BV (INR)	245.2	297.0	347.0	403.3	465.7
Adj. BVPS growth (%)	17.3	21.2	16.8	16.2	15.5
RoA (%)	0.8	1.0	1.0	1.1	1.1
RoE (%)	16.1	18.1	18.1	18.4	17.8
P/E (x)	10.0	7.8	6.7	5.7	5.1
P/ABV (x)	1.8	1.5	1.3	1.1	0.9

Source: Company, Emkay Research

Growth trajectory improves, but NIMs dip a bit

SBI reported better growth in Q3 at 15% YoY/5% QoQ, led by improved corporate, SME, and agri growth. Within retail, Xpress credit book continued to expand at a faster pace, but the bank has raised lending rates due to higher risk weights being directed by the RBI. Deposit growth was largely in line with systematic growth at 13% YoY/1.6% QoQ, leading to better LDR at 75%. However, higher cost of funds led to a 7bps decline in NIM to 3.2%. Going forward, the bank expects growth to remain range-bound, while margin is expected to stabilize, aided by better LDR and the recent rate hike. Staff cost could remain elevated in Q4 due to pending wage revision/retirement provision of Rs54bn and, thus, overall staff cost for FY24E would be at Rs770bn, but it should moderate at Rs660bn in FY25E as catch-up wage revision provisions are absent, thereby leading to lower cost/income ratio.

NPA ratio continues to trend down

Gross slippages inched up a bit during the quarter to Rs50.5bn/0.6% of loans mainly due to recognition of BGR Energy as per RBI's diktat, but better growth led to a sustained decline in GNPA ratio to 2.4%. The restructured pool decelerated further to Rs188bn/0.5% of loans vs. 0.6% in Q2. The bank once again reassured that its retail book, including PL, remains better off, given the loans being mainly extended to captive customers. That said, we believe the bank should be cautious in sourcing portfolios via NBFCs amid rising asset-quality noise.

Retain BUY with a revised TP of Rs750

SBI's CET-1 stands low at 10.4% (incl. 9M profit). Thus, the bank has now indicated to raise capital soon. We have trimmed our FY24 estimates by 6%, factoring in higher staff cost, but we have revised upwards our FY25/26 estimates by 3%/9% due to better margins, treasury performance, and sustained lower LLP. We retain BUY with a revised TP of Rs750/share, rolling forward on Dec-25E standalone Bank ABV, and have revised subsidiaries/investments value at Rs210/share (vs. Rs185). **Key risks:** Severe macro dislocation and a prolonged elevated-rate environment hurting margins and leading to growth/asset-quality disruption.



TARGET PRICE (Rs): 750

Dec-24
7.1
BUY
BUY
15.4
649.7
Ticker
661
502
8,924.6
5,798
69,917
NA
17
10,433.9
125.8
43.0
21,854
82.9
56.9

Price Performance							
(%)	1M	3M	12M				
Absolute	1.6	13.6	23.0				
Rel. to Nifty	0.7	(0.6)	(0.9)				

10.8/23.9



FPIs/MFs (%)



Anand Dama

anand.dama@emkayglobal.com +91 22 6624 2480

Kunaal N

kunaal.n@emkayglobal.com +91 22 6612 1275

Marazbaan Dastur

marazbaan.dastur@emkayglobal.com +91 22 6612 1281

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 05/01/2024 10:15 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAYsGO>Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Story in Charts

Exhibit 1: Credit growth improves in **Q**3, led by traction in corporate, SME, and agri book






Exhibit 2: NIM takes a slight dip owing to rising CoFs



Source: Company, Emkay Research

Exhibit 3: CASA cannibalization continues, but the bank does not plan any increase in SA rate



Source: Company, Emkay Research


Exhibit 5: GNPA ratio continued to trend down

PCR (%) GNPA Ratio (%) NNPA Ratio (%) 5.0 80 4.0 74 75 3.0 70 2.0 65 1.0 0.0 60 3QFY24 1QFY24 3QFY22 4QFY22 **QFY23** 2QFY23 3QFY23 4QFY23 2QFY24

Source: Company, Emkay Research


Source: Company, Emkay Research

Exhibit 4: Slippages were up a bit QoQ due to the recognition of a corporate a/c



Source: Company, Emkay Research

Exhibit 6: Higher staff cost contained RoA at 1%



Source: Company, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 05/01/2024 10:15 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore. Emkay Resear

Exhibit 7: SBI to report a healthy RoA/RoE trajectory (without E factoring in capital raise)






Exhibit 8: We value the standalone bank at 1.2x Dec-25E ABV and subsidiaries/investments at Rs210/share



Source: Emkay Research

Source: Emkay Research

Exhibit 9: The stock currently trades at 1.2x its one-year forward ABV



Source: Company, Emkay Research

Exhibit 10: Actuals vs. Estimates (Q3FY24)

(Rs mn)	Actuals	Estir	nates	Var	riation	Comments
	Actuals	Emkay	Consensus	Emkay	Consensus	
Net income	512,746	516,489	477,869	-1%	7%	Slight compression in NIMs led to a slight miss
PPOP	132,361	204,191	236,012	-35%	-44%	One-off staff expenses led to a miss
ΡΑΤ	91,640	145,127	145,758	-37%	-37%	Lower PPOP partly offset by lower provisions led to a miss

Source: Company, Emkay Research

Exhibit 11: Quarterly Summary

(Rs mn)	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	YoY (%)	QoQ (%)	FY23A	FY24E	YoY (%)
Interest Earned	866,160	929,511	959,755	1,013,788	1,067,338	23	5	3,321,031	4,153,693	25
Interest Exp.	485,474	525,586	570,705	618,788	669,181	38	8	1,872,626	2,568,243	37
Net Interest Income	380,686	403,925	389,050	395,000	398,157	5	1	1,448,405	1,585,450	9
Global NIM (Reported)	3.50	3.60	3.33	3.29	3.22	-28bps	-7bps	3.01	2.97	-4bps
Non-interest Income	114,677	139,614	120,634	107,906	114,589	0	6	366,156	476,065	30
Operating Expenses	243,171	297,328	256,714	308,740	380,386	56	23	977,431	1,228,468	26
Pre Provisioning Profit	252,193	246,211	252,969	194,166	132,361	-48	-32	837,130	833,048	0
Provision and Contingencies	57,606	33,157	25,013	1,153	6,879	-88	497	165,073	49,904	-70
PBT	194,587	213,054	227,956	193,013	125,482	-36	-35	672,057	783,144	17
Income Tax Expense (Gain)	52,534	46,109	59,113	49,713	33,843	-36	-32	169,732	197,352	16
Net Profit/(Loss)	142,053	166,945	168,843	143,300	91,640	-35	-36	502,325	585,792	17
Gross NPA (%)	3.14	2.78	2.76	2.55	2.42	-72bps	-13bps	2.78	2.26	-53bps
Net NPA (%)	0.77	0.67	0.71	0.64	0.64	-13bps	0bps	0.67	0.57	-10bps
Deposits (Rs bn)	42,136	44,238	45,312	46,892	47,622	13	2	44,238	49,275	11
Net Advances (Rs bn)	30,582	31,993	32,350	33,452	35,195	15	5	31,993	36,633	15

Source: Company, Emkay Research

Exhibit 12: Revision in Estimates

Y/E March (Rs mn)		FY24E		FY25E			FY26E		
	Earlier	Revised	Change	Earlier	Revised	Change	Earlier	Revised	Change
Net interest income	1,587,813	1,585,450	-0.1%	1,801,844	1,741,136	-3.4%	2,001,409	1,928,882	-3.6%
РРОР	910,059	833,048	-8.5%	1,057,283	1,104,925	4.5%	1,215,705	1,275,477	4.9%
PAT	620,000	585,792	-5.5%	667,538	685,955	2.8%	707,643	771,498	9.0%
EPS (Rs)	69.5	65.6	-5.5%	74.8	76.9	2.8%	79.3	86.4	9.0%
BV (Rs)	391.5	387.6	-1.0%	451.3	449.5	-0.4%	514.5	519.9	1.0%

Source: Emkay Research

Exhibit 13: Key Assumption	ons			
(%)	FY23A	FY24E	FY25E	FY26E
Loan Growth	17.0	14.5	13.2	15.0
Deposit Growth	9.2	11.4	13.6	16.0
NIM	3.0	3.0	2.9	2.9
GNPA	2.8	2.3	2.1	2.2
Credit Cost	0.5	0.3	0.5	0.6

Source: Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 05/01/2024 10:15 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Q3FY24

35,195

15.1

5.2

29.1

36.8

11.9

15.7

6.5

39.5

34.3

3.22 3.34

2.4

0.6

50 0.7

74.2

13.1

10.6 9.1

2.7

0.6

0.2

2.6

0.9

0.0

0.9

0.2

0.6

16.2

10.1

5.2

	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24
Loans (Rs bn)	25,784	27,340	28,152	29,513	30,582	31,993	32,350	33,452
Loan growth (YoY)	8.9	11.6	15.8	20.8	18.6	17.0	14.9	13.3
Loan growth (QoQ)	5.5	6.0	3.0	4.8	3.6	4.6	1.1	3.4
Loan composition (%)								
Corporate	30.4	31.8	31.0	31.1	30.2	30.6	30.4	29.2
Retail	36.9	36.7	36.7	36.4	36.8	36.9	37.2	37.2
SME	11.9	11.2	11.1	10.7	11.5	11.2	11.4	11.6
Overseas	15.5	15.0	16.0	16.5	15.9	15.4	14.9	15.7
Agri	5.3	5.3	5.1	5.3	5.6	5.9	6.1	6.2
Liability Profile and Margins (%)								
CASA	44.2	43.8	43.7	42.9	42.7	42.1	41.2	40.2
CA	5.9	6.5	5.8	5.6	5.4	6.4	5.7	5.4
SA	38.3	37.3	37.9	37.4	37.3	35.7	35.5	34.8
Global NIM (%)	3.11	3.12	3.02	3.32	3.50	3.60	3.33	3.29
Domestic NIM (%)	3.35	3.36	3.23	3.39	3.69	3.58	3.47	3.43
Asset Quality								
GNPA (%)	4.5	4.0	3.9	3.5	3.1	2.8	2.8	2.6
NNPA (%)	1.3	1.0	1.0	0.8	0.8	0.7	0.7	0.6
PCR (%)	71.2	75.0	75.1	77.9	76.1	76.4	74.8	74.5
Slippages (Rs bn)	26	36	101	24	32	35	79	41
Slippages (%)	0.4	0.6	1.7	0.4	0.5	0.5	1.1	0.6
Capital Adequacy								
CAR (%)	13.2	13.8	13.4	13.5	13.3	14.7	14.6	14.3
Tier I (%)	10.9	11.4	11.2	11.1	10.8	12.1	12.0	11.8
CET 1 (%)	10.3	9.9	9.7	9.5	9.3	10.3	10.2	9.9
ROE decomposition on total assets (%)								
NII	2.6	2.5	2.5	2.8	2.9	3.0	2.8	2.8
Other Income (Ex Treasury)	0.7	1.0	0.7	0.7	0.6	0.9	0.6	0.6
Treasury	0.0	0.0	-0.5	0.0	0.2	0.1	0.3	0.1
Opex	1.8	1.9	1.7	1.8	1.8	2.2	1.9	2.2
РРОР	1.6	1.6	1.0	1.7	1.9	1.8	1.8	1.4
Provisioning Cost	0.6	0.6	0.4	0.2	0.4	0.2	0.2	0.0
РВТ	1.0	1.0	0.7	1.4	1.5	1.6	1.6	1.4
Tax	0.3	0.3	0.2	0.4	0.4	0.3	0.4	0.3
ROA	0.7	0.7	0.5	1.0	1.1	1.2	1.2	1.0
Leverage (x)	17.5	17.6	17.5	17.1	16.8	16.7	16.5	16.2
ROE	12.4	13.1	8.5	17.8	18.2	20.6	20.1	16.3

Source: Company, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 05/01/2024 10:15 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

State Bank of India: Standalone Financials and Valuations

Profit and Loss					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Interest Income	2,754,573	3,321,031	4,153,693	4,505,705	4,887,747
Interest Expense	1,547,497	1,872,626	2,568,243	2,764,569	2,958,864
Net interest income	1,207,076	1,448,405	1,585,450	1,741,136	1,928,882
NII growth (%)	9.0	20.0	9.5	9.8	10.8
Other income	405,639	366,156	476,065	534,579	612,738
Total Income	1,612,715	1,814,561	2,061,515	2,275,715	2,541,620
Operating expenses	859,792	977,431	1,228,468	1,170,790	1,266,143
PPOP	752,923	837,130	833,048	1,104,925	1,275,477
PPOP growth (%)	5.2	11.2	(0.5)	32.6	15.4
Core PPOP	720,705	850,674	715,482	956,543	1,109,558
Provisions & contingencies	244,521	165,073	49,904	187,873	244,062
PBT	508,402	672,057	783,144	917,052	1,031,415
Extraordinary items	0	0	0	0	0
Tax expense	117,459	169,732	197,352	231,097	259,917
Minority interest	0	0	0	0	C
Income from JV/Associates	0	0	0	0	0
Reported PAT	390,943	502,325	585,792	685,955	771,498
PAT growth (%)	91.5	28.5	16.6	17.1	12.5
Adjusted PAT	390,943	502,325	585,792	685,955	771,498
Diluted EPS (Rs)	35.5	56.3	65.6	76.9	86.4
Diluted EPS growth (%)	55.2	58.6	16.6	17.1	12.5
DPS (Rs)	7.1	11.3	14.0	15.0	16.0
Dividend payout (%)	16.2	20.1	21.3	19.5	18.5
Effective tax rate (%)	23.1	25.3	25.2	25.2	25.2
Net interest margins (%)	2.8	3.0	3.0	2.9	2.9
Cost-income ratio (%)	53.3	53.9	59.6	51.4	49.8
Shares outstanding (mn)	8,924.6	8,924.6	8,924.6	8,924.6	8,924.6

Balance Sheet					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	8,925	8,925	8,925	8,925	8,92
Reserves & surplus	2,791,956	3,267,160	3,728,007	4,280,092	4,908,796
Net worth	2,800,881	3,276,085	3,736,932	4,289,017	4,917,720
Deposits	40,515,341	44,237,778	49,274,613	55,954,612	64,892,775
Borrowings	4,260,434	4,931,352	5,566,249	5,871,560	5,711,03
Interest bearing liab.	44,775,775	49,169,129	54,840,862	61,826,172	70,603,800
Other liabilities & prov.	2,299,318	2,724,571	2,810,733	2,442,165	2,436,100
Total liabilities & equity	49,875,974	55,169,785	61,388,527	68,557,354	77,957,626
Net advances	27,339,666	31,992,693	36,633,294	41,469,780	47,690,548
Investments	14,814,455	15,703,662	17,079,061	18,678,306	20,644,065
Cash, other balances	3,945,523	3,078,996	2,742,043	3,091,309	3,883,209
Interest earning assets	27,339,666	31,992,693	36,633,294	41,469,780	47,690,548
Fixed assets	377,082	423,818	482,201	529,307	581,049
Other assets	3,399,249	3,970,616	4,451,928	4,788,653	5,158,754
Total assets	49,875,974	55,169,785	61,388,527	68,557,354	77,957,626
BVPS (Rs)	268.6	315.0	366.7	426.4	494.6
Adj. BVPS (INR)	245.2	297.0	347.0	403.3	465.7
Gross advances	28,180,239	32,687,307	37,263,530	42,107,789	48,423,957
Credit to deposit (%)	67.5	72.3	74.3	74.1	73.5
CASA ratio (%)	44.5	42.7	39.8	39.0	39.0
Cost of deposits (%)	3.7	3.8	4.8	4.6	4.5
Loans-to-Assets (%)	54.8	58.0	59.7	60.5	61.2
Net advances growth (%)	11.6	17.0	14.5	13.2	15.0
Deposit growth (%)	10.1	9.2	11.4	13.6	16.0
Book value growth (%)	12.0	17.3	16.4	16.3	16.0

Source: Company, Emkay Research

Source: Company, Emkay Research

Asset Quality and Ot	her M				
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Asset quality					
Gross NPLs	1,120,233. 7	909,281.5	840,315.4	886,123.8	1,047,727. 4
Net NPLs	279,660.9	214,667.3	210,078.8	248,114.7	314,318.2
GNPA ratio (%)	4.0	2.8	2.3	2.1	2.2
NNPA ratio (%)	1.0	0.7	0.6	0.6	0.7
Provision coverage (%)	75.0	76.4	75.0	72.0	70.0
Gross slippages	250,212.3	192,230.0	231,033.9	315,808.4	411,603.6
Gross slippage ratio (%)	0.9	0.6	0.6	0.8	0.9
LLP ratio (%)	10.1	6.6	5.6	5.8	6.3
NNPA to networth (%)	1.0	0.7	0.6	0.6	0.7
Capital adequacy					
Total CAR (%)	13.8	14.7	14.1	13.7	13.2
Tier-1 (%)	11.4	12.1	11.8	11.6	11.3
CET-1 (%)	9.9	10.3	10.2	10.3	10.1
RWA-to-Total Assets (%)	55.0	50.5	53.0	55.0	57.0
Miscellaneous					
Total income growth (%)	2.4	16.7	25.6	8.9	9.1
Opex growth (%)	4.0	13.7	25.7	(4.7)	8.1
Core PPOP growth (%)	10.0	18.0	(15.9)	33.7	16.0
PPOP margin (%)	23.8	22.7	18.0	21.9	23.2
PAT/PPOP (%)	51.9	60.0	70.3	62.1	60.5
LLP-to-Core PPOP (%)	33.9	19.4	7.0	19.6	22.0
Yield on advances (%)	6.7	7.5	8.5	8.2	7.8
Cost of funds (%)	3.6	4.0	4.9	4.7	4.5

Valuations and Key Ratios Y/E Mar FY22 FY23 FY24E FY25E FY26E P/E (x) 10.0 7.8 6.7 5.7 5.1 P/B (x) 1.4 1.2 0.9 1.6 1.0 P/ABV (x) 1.8 1.5 1.3 0.9 1.1 P/PPOP (x) 5.2 4.7 4.7 3.6 3.1 Dividend vield (%) 1.7 2.2 2.5 1.1 2.3 DuPont-RoE split (%) NII/avg assets 2.5 2.8 2.7 2.7 2.6 Other income 0.9 0.7 0.8 0.8 0.8 0.5 0.8 Fee income 0.7 0.7 0.8 Opex 1.8 1.9 2.1 1.8 1.7 PPOP 1.6 1.6 1.4 1.7 1.7 Core PPOP 1.5 1.5 1.6 1.2 1.5 Provisions 0.5 0.3 0.1 0.3 0.3 Tax expense 0.2 0.3 0.3 0.4 0.4 1.1 RoA (%) 0.8 1.0 1.0 1.1 19.6 18.9 18.0 17.4 16.9 Leverage ratio (x) RoE (%) 16.1 18.1 18.1 18.4 17.8 **Quarterly data** Rs mn, Y/E Mar **O3FY23** 04FY23 01FY24 **02FY24 O3FY24** NII 380,686 403,925 389,050 398,157 395.000 NIM (%) 3.5 3.6 3.3 3.3 3.2 PPOP 252,193 246,211 252,969 194,166 132,361 PAT 142,053 166,945 168,843 143,300 91,640 EPS (Rs) 15.92 18.71 18.92 16.06 10.27

Source: Company, Emkay Research

Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions.com use and downloaded at 05/01/2024 10:15 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
30-Nov-23	565	700	Buy	Anand Dama
05-Nov-23	578	700	Buy	Anand Dama
05-Aug-23	573	700	Buy	Anand Dama
19-May-23	575	700	Buy	Anand Dama
19-May-23	575	700	Buy	Anand Dama
09-Mar-23	559	715	Buy	Anand Dama
04-Feb-23	544	715	Buy	Anand Dama
05-Nov-22	594	715	Buy	Anand Dama
06-Aug-22	531	640	Buy	Anand Dama
15-May-22	445	640	Buy	Anand Dama
24-Mar-22	487	680	Buy	Anand Dama
06-Feb-22	530	680	Buy	Anand Dama
03-Nov-21	528	680	Buy	Anand Dama
05-Jul-21	433	600	Buy	Anand Dama
23-May-21	401	600	Buy	Anand Dama
05-Feb-21	393	460	Buy	Anand Dama

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

Source: Company, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 05/01/2024 10:15 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014, EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 05/01/2024 10:15 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGESL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1. the securities recommended in this report as of February 4, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- З EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of February 4, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the 5. subject company at the end of the month immediately preceding the February 4, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for
- investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkavglobal.com

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 05/01/2024 10:15 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject Company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.